Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis

被引：13

作者：

Hayashi, T ^{[1
]}

Yamaguchi, I ^{[1
]}

Saitoh, H ^{[1
]}

Takagi, M ^{[1
]}

Nonaka, Y ^{[1
]}

Nomura, T ^{[1
]}

机构：

[1] Tokyo Metropolitan Police Hosp, Div Internal Med, Chiyoda Ku, Tokyo 1028161, Japan

来源：

INTERNAL MEDICINE | 2003年 / 42卷 / 07期

关键词：

IgD myeloma; renal failure; hemodialysis; thalidomide; optional treatment; adverse effect;

D O I：

10.2169/internalmedicine.42.605

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 64-year-old Japanese man suffering from IgD lambda myeloma and renal failure requiring chronic hemodialysis was treated with thalidomide. Serum IgD concentration was 4,050 mg/dl and myeloma cells constituted 95.6% of nucleated cells in bone marrow at the start of treatment. These parameters improved markedly to 1,590 mg/dl and 22.0%, respectively, in the 4 months immediately prior to his death due to pneumonia. Thalidomide caused peripheral neuropathy and constipation at a dose of 100 mg daily in the first week of treatment, but adverse effects resolved upon dose reduction. Thalidomide represents a valid therapeutic option for some myeloma patients receiving hemodialysis.

引用

页码：605 / 608

页数：4

共 10 条

[1] Thalidomide in the management of multiple myeloma [J].

Barlogie, B ;

Zangari, M ;

Spencer, T ;

Fassas, A ;

Anaissie, E ;

Badros, A ;

Cromer, J ;

Tricot, G .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :250-259

[2] IMMUNOGLOBULIN-D MULTIPLE-MYELOMA - PRESENTING FEATURES, RESPONSE TO THERAPY, AND SURVIVAL IN A SERIES OF 53 CASES [J].

BLADE, J ;

LUST, JA ;

KYLE, RA .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2398-2404

[3]

IGGO N, 1989, Q J MED, V73, P903

[4] IGD MULTIPLE-MYELOMA - REVIEW OF 133 CASES [J].

JANCELEWICZ, Z ;

TAKATSUKI, K ;

SUGAI, S ;

PRUZANSKI, W .

ARCHIVES OF INTERNAL MEDICINE, 1975, 135 (01) :87-93

[5] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].

Juliusson, G ;

Celsing, F ;

Turesson, I ;

Lenhoff, S ;

Adriansson, M ;

Malm, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96

[6]

PASQUALI S, 1990, CLIN NEPHROL, V34, P247

[7]

SHIMAMOTO Y, 1995, CANCER DETECT PREV, V19, P426

[8] THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL [J].

SILVA, SRB ;

VIANA, PCF ;

LUGON, NV ;

HOETTE, M ;

RUZANY, F ;

LUGON, JR .

NEPHRON, 1994, 67 (03) :270-273

[9] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[10] Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses [J].

Tseng, S ;

Pak, G ;

Washenik, K ;

Pomeranz, MK ;

Shupack, JL .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 35 (06) :969-979

← 1 →